MCID: PRS045
MIFTS: 45

Prostatic Hypertrophy malady

Categories: Reproductive diseases

Aliases & Classifications for Prostatic Hypertrophy

Aliases & Descriptions for Prostatic Hypertrophy:

Name: Prostatic Hypertrophy 12 14 69
Benign Prostatic Hypertrophy 69
Prostatic Hyperplasia 69

Classifications:



External Ids:

Disease Ontology 12 DOID:11132

Summaries for Prostatic Hypertrophy

MalaCards based summary : Prostatic Hypertrophy, also known as benign prostatic hypertrophy, is related to prostatitis and hole retinal cyst, and has symptoms including prostatism An important gene associated with Prostatic Hypertrophy is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Pathways in cancer and Glioma. The drugs Alfuzosin and Tamsulosin have been mentioned in the context of this disorder. Affiliated tissues include prostate, heart and kidney, and related phenotypes are behavior/neurological and cardiovascular system

Related Diseases for Prostatic Hypertrophy

Diseases related to Prostatic Hypertrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 119)
id Related Disease Score Top Affiliating Genes
1 prostatitis 10.9
2 hole retinal cyst 10.3 AR KLK3
3 prostate cancer 10.3
4 bartholin's gland benign neoplasm 10.3 ESR1 PGR
5 dystonia-parkinsonism, x-linked 10.3 AR CYP19A1
6 cardiovascular organ benign neoplasm 10.3 ESR1 PGR
7 appendix leiomyoma 10.3 ESR1 PGR
8 bronchus adenoma 10.3 ESR1 PGR
9 glioma 10.3 ESR1 PGR
10 ovarian benign neoplasm 10.3 ESR1 PGR
11 plexiform neurofibroma 10.3 ESR1 PGR
12 paranasal sinus disease 10.3 ESR1 PGR
13 x-linked leigh syndrome 10.3 AR ESR1
14 deafness, autosomal recessive 21 10.3 ESR1 PGR
15 ulceroglandular tularemia 10.3 AR ESR1
16 colon signet ring adenocarcinoma 10.3 AR KLK3
17 cervical lymphoepithelioma-like carcinoma 10.2 ESR1 PGR
18 histiocytic and dendritic cell cancer 10.2 ESR1 PGR
19 atypical lipomatous tumor 10.2 ESR1 PGR
20 pediatric intraocular retinoblastoma 10.2 ESR1 PGR
21 congenital disorder of glycosylation, type ic 10.2 ESR1 PGR
22 intestinal perforation 10.2 ESR1 PGR
23 borderline personality disorder 10.2 AR CYP19A1
24 perlman syndrome 10.2 ESR1 PGR
25 bladder adenocarcinoma 10.2 ESR1 PGR
26 biemond syndrome 10.2 CYP19A1 PGR
27 vulva basal cell carcinoma 10.2 ESR1 PGR
28 villoglandular endometrial endometrioid adenocarcinoma 10.2 ESR1 PGR
29 vaginal adenosarcoma 10.2 ESR1 PGR
30 panophthalmitis 10.2 CYP19A1 PGR
31 glioblastoma mesenchymal subtype 10.2 AR CYP19A1 KLK3
32 intraneural perineurioma 10.2 ESR1 PGR
33 paraphimosis 10.2 ESR1 PGR
34 skin hemangioma 10.2 AR CYP19A1 KLK3
35 malignant teratocarcinosarcoma 10.2 ALPP AR
36 central nervous system mature teratoma 10.2 ESR1 PGR
37 biliary tract neoplasm 10.2 ESR1 KLK3 PGR
38 benign fibrous mesothelioma 10.2 EGF ESR1
39 leukoencephalopathy with ataxia 10.2 AR CYP19A1
40 her2-receptor negative breast cancer 10.2 CYP19A1 ESR1 PGR
41 necrobiosis lipoidica 10.2 ESR1 KLK3 PGR
42 benign shuddering attacks 10.2 AR CYP19A1 ESR1
43 acute thyroiditis 10.2 CYP19A1 ESR1 PGR
44 perinatal jaundice due to hepatocellular damage 10.1 CYP19A1 ESR1 PGR
45 intraventricular meningioma 10.1 AR SRY
46 bowman's membrane folds or rupture 10.1 AR PGR
47 glycerol kinase deficiency, adult form 10.1 CYP19A1 ESR1 PGR
48 nervous system hibernoma 10.1 AR ESR1 PGR
49 breast duct papilloma 10.1 CYP19A1 ESR1 PGR
50 anal neuroendocrine tumor 10.1 AR ESR1 PGR

Comorbidity relations with Prostatic Hypertrophy via Phenotypic Disease Network (PDN): (show top 50) (show all 52)


Acute Cystitis Acute Kidney Failure
Anthracosis Asbestosis
Balanoposthitis Bladder Disease
Bladder Neck Obstruction Chronic Kidney Failure
Chronic Myocardial Ischemia Cystitis
Cystitis Cystica Epididymo-Orchitis
First-Degree Atrioventricular Block Generalized Atherosclerosis
Gout Hydronephrosis
Infected Hydrocele Interstitial Cystitis
Ischemic Heart Disease Kidney Disease
Left Bundle Branch Hemiblock Lipoma of Spermatic Cord
Low Compliance Bladder Nephrolithiasis, Type I
Neurogenic Bladder Parkinson Disease, Late-Onset
Pelvic Varices Penile Disease
Peyronie's Disease Pinta Disease
Pneumoconiosis Postinflammatory Pulmonary Fibrosis
Prostate Calculus Prostate Cancer
Prostate Carcinoma in Situ Prostate Disease
Prostatitis Prostatocystitis
Renal Pelvis Carcinoma Right Bundle Branch Block
Silicosis Spermatocele
Ureter Cancer Ureterolithiasis
Urethral Benign Neoplasm Urethral Calculus
Urethral Stricture Urethritis
Urinary Bladder Cancer Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Prostatic Hypertrophy:



Diseases related to Prostatic Hypertrophy

Symptoms & Phenotypes for Prostatic Hypertrophy

UMLS symptoms related to Prostatic Hypertrophy:


prostatism

MGI Mouse Phenotypes related to Prostatic Hypertrophy:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.01 ADRA1A AR CD36 CYP19A1 ESR1 FGF8
2 cardiovascular system MP:0005385 9.91 ADRA1A AR CD36 CYP19A1 ESR1 FGF8
3 digestive/alimentary MP:0005381 9.8 AR CD36 CYP19A1 EGF ESR1 FGF8
4 endocrine/exocrine gland MP:0005379 9.8 AR CD36 CYP19A1 EGF ESR1 FGF8
5 immune system MP:0005387 9.76 CYP19A1 EGF ESR1 FGF8 LGALS8 PGR
6 muscle MP:0005369 9.5 ADRA1A AR CD36 CYP19A1 ESR1 FGF8
7 renal/urinary system MP:0005367 9.1 ADRA1A AR CD36 CYP19A1 ESR1 FGF8

Drugs & Therapeutics for Prostatic Hypertrophy

Drugs for Prostatic Hypertrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 106)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alfuzosin Approved, Investigational Phase 4,Phase 3,Phase 2 81403-80-7 2092
2
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 1 106133-20-4 129211
3
Silodosin Approved Phase 4 160970-54-7
4
Mivacurium Approved Phase 4 106791-40-6, 133814-19-4 5281042
5
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
6
Dihydrotachysterol Approved Phase 4 67-96-9 5281010 5311071
7
Dutasteride Approved, Investigational Phase 4,Phase 3,Phase 2 164656-23-9 152945 6918296
8
Methyltestosterone Approved Phase 4,Phase 3,Phase 2 58-18-4 6010
9
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2 58-22-0 6013
10
Doxazosin Approved Phase 4,Phase 3 74191-85-8 3157
11
Mirabegron Approved Phase 4 223673-61-8
12
Dihydrotestosterone Illicit Phase 4 521-18-6 10635
13 Adrenergic Agents Phase 4,Phase 3,Phase 2
14 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3,Phase 2
15 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2
16 Adrenergic Antagonists Phase 4,Phase 3,Phase 2
17 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
18 Anesthetics Phase 4
19 Cholinergic Agents Phase 4,Phase 3,Phase 2
20 Neuromuscular Agents Phase 4,Phase 3,Phase 2
21 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
22
Atracurium Phase 4 64228-79-1 47319
23 Cholinergic Antagonists Phase 4
24 Neuromuscular Blocking Agents Phase 4
25 Neuromuscular Nondepolarizing Agents Phase 4
26 Muscarinic Antagonists Phase 4
27 Solifenacin succinate Phase 4 242478-38-2
28 5-alpha Reductase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
29 Anabolic Agents Phase 4,Phase 2
30 Androgens Phase 4,Phase 3,Phase 2
31 Antineoplastic Agents, Hormonal Phase 4,Phase 2
32 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
33 Hormones Phase 4,Phase 3,Phase 1,Phase 2
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
35 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
36 Testosterone 17 beta-cypionate Phase 4,Phase 3,Phase 2
37
Testosterone enanthate Phase 4,Phase 3,Phase 2 315-37-7 9416
38 Testosterone undecanoate Phase 4,Phase 3,Phase 2
39 Antihypertensive Agents Phase 4,Phase 3
40 Adrenergic Agonists Phase 4
41 Adrenergic beta-3 Receptor Agonists Phase 4
42 Adrenergic beta-Agonists Phase 4
43
Acetylcholine Approved Phase 3,Phase 2 51-84-3 187
44
Cetrorelix Approved, Investigational Phase 3 120287-85-6 16129715 25074887
45
Finasteride Approved Phase 3,Phase 1,Phase 2 98319-26-7 57363
46
Tadalafil Approved, Investigational Phase 3,Phase 2,Phase 1 171596-29-5 110635
47
Magnesium oxide Approved Phase 3 1309-48-4 14792
48
Metformin Approved Phase 3 657-24-9 14219 4091
49
Inulin Approved, Nutraceutical Phase 3 9005-80-5 24763
50 abobotulinumtoxinA Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 94)
id Name Status NCT ID Phase
1 Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy Completed NCT00542165 Phase 4
2 Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH Completed NCT01260129 Phase 4
3 Effect of Deep BLock on Intraoperative Surgical Conditions Completed NCT01631149 Phase 4
4 Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia Completed NCT00771394 Phase 4
5 Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement Completed NCT00752869 Phase 4
6 Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer Completed NCT00375765 Phase 4
7 Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction Completed NCT00827814 Phase 4
8 Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years Completed NCT02757963 Phase 4
9 Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement Completed NCT01294592 Phase 4
10 Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement Completed NCT00648323 Phase 4
11 TRADE-Testosterone Replacement and Dutasteride Effectiveness Completed NCT00194675 Phase 4
12 Efficacy of Prunus Domestica Extract in BPH Completed NCT02702947 Phase 4
13 Alpha-Blockers in Allergic Rhinitis (MAN 01) Completed NCT01946035 Phase 4
14 A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH) Active, not recruiting NCT02656173 Phase 4
15 Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia Repair Enrolling by invitation NCT02958878 Phase 4
16 A-botulinic Toxin for Symptomatic Benign Prostate Hypertrophy Unknown status NCT01275521 Phase 3
17 Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) Completed NCT00663858 Phase 3
18 The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate Completed NCT00427219 Phase 2, Phase 3
19 Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH) Completed NCT00670306 Phase 3
20 Medical Therapy of Prostatic Symptoms (MTOPS) Completed NCT00021814 Phase 3
21 Clinical Trial in Males With BPH (Enlarged Prostate) Completed NCT00029822 Phase 3
22 "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk Completed NCT00056407 Phase 3
23 A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms Completed NCT01139762 Phase 3
24 Intraprostatic Botulinum Toxin Type "A" Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical Therapy Completed NCT01566292 Phase 2, Phase 3
25 Combination of Metformine/Inulin Versus Metformin on Prostate Benign Hyperplasia in Metabolic Syndrome Completed NCT02778776 Phase 3
26 Study to Assess the Efficacy of Medi-Tate TIND Device Active, not recruiting NCT02145208 Phase 3
27 Cetrorelix Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) Terminated NCT00449150 Phase 3
28 JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Terminated NCT01830829 Phase 3
29 Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS) Terminated NCT00688948 Phase 2, Phase 3
30 H-36731: Finasteride in Management of Elevated Red Blood Cells Withdrawn NCT02548117 Phase 3
31 A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH). Unknown status NCT00044226 Phase 2
32 Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy Completed NCT00461123 Phase 2
33 Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT00386009 Phase 2
34 Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate) Completed NCT00037141 Phase 1, Phase 2
35 A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After Supplementation Completed NCT00154843 Phase 2
36 Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT01227993 Phase 1, Phase 2
37 5-Alpha Reductase and Anabolic Effects of Testosterone Completed NCT00475501 Phase 2
38 Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone Completed NCT00161421 Phase 2
39 Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH) Recruiting NCT02676544 Phase 1, Phase 2
40 Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Recruiting NCT02961114 Phase 1, Phase 2
41 Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams Recruiting NCT02396420 Phase 2
42 Testosterone Plus Finasteride Treatment After Spinal Cord Injury Recruiting NCT02248701 Phase 2
43 Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy Active, not recruiting NCT01446991 Phase 2
44 Use of a Novel Radiopaque Embolic Agent in Prostatic Artery Embolisation for Symptomatic Benign Prostatic Enlargement Not yet recruiting NCT03109925 Phase 2
45 A Study in Men With Benign Prostatic Hyperplasia Terminated NCT01097707 Phase 2
46 A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806) Terminated NCT00651807 Phase 2
47 Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH) Completed NCT01330927 Phase 1
48 Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia Recruiting NCT02592473 Phase 1
49 A Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 in Healthy Male Subjects Not yet recruiting NCT02615782 Phase 1
50 Feasibility Study of Photovaporisation of Prostate With a Limitated Length of Catheterization of 3 Hours Unknown status NCT02401581

Search NIH Clinical Center for Prostatic Hypertrophy

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Prostatic Hypertrophy

Anatomical Context for Prostatic Hypertrophy

MalaCards organs/tissues related to Prostatic Hypertrophy:

39
Prostate, Heart, Kidney, Breast, Smooth Muscle, Colon, Appendix

Publications for Prostatic Hypertrophy

Articles related to Prostatic Hypertrophy:

(show top 50) (show all 534)
id Title Authors Year
1
Prostate Artery Embolization for Complete Urinary Outflow Obstruction Due to Benign Prostatic Hypertrophy. ( 27853823 )
2017
2
Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with I+-blockers. ( 27629686 )
2016
3
Re: Stroke Associated with Alpha Blocker Therapy for Benign Prostatic Hypertrophy. ( 27321530 )
2016
4
Inhibitory Activities of Phenolic Compounds Isolated from Adina rubella Leaves Against 5I+-Reductase Associated with Benign Prostatic Hypertrophy. ( 27399661 )
2016
5
The Impact of Medical and Surgical Treatment for Benign Prostatic Hypertrophy on Erectile Function. ( 26438220 )
2015
6
Kidney transplant complications from undiagnosed benign prostatic hypertrophy. ( 25832848 )
2015
7
Supplementary management of benign prostatic hypertrophy with Prostaquil. An 8-week registry. ( 26492588 )
2015
8
Clinical Outcomes of Transurethral Enucleation with Bipolar for Benign Prostatic Hypertrophy. ( 26662662 )
2015
9
Effects of I+-blocker therapy on active duty military and military retirees for benign prostatic hypertrophy on diabetic complications. ( 25735029 )
2015
10
The Role of Minimally Invasive Surgical Techniques in the Management of Large-gland Benign Prostatic Hypertrophy. ( 26543428 )
2015
11
Varicocele: the origin of benign prostatic hypertrophy? Testosterone dosages in the periprostatic plexus. ( 26290288 )
2015
12
Tadalafil and benign prostatic hypertrophy. Too risky. ( 24860894 )
2014
13
Efficacy of Long-Term Daily Dosage of Alfuzosin 10 mg upon Sexual Function of Benign Prostatic Hypertrophy Patients: Two-Year Prospective Observational Study. ( 25606561 )
2014
14
Surgical therapy for benign prostatic hypertrophy/bladder outflow obstruction. ( 24744521 )
2014
15
Bilateral ureteral obstruction revealing a benign prostatic hypertrophy: a case report and review of the literature. ( 24513237 )
2014
16
Re: a phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. ( 25629105 )
2014
17
Bipolar transurethral resection versus monopolar transurethral resection for benign prostatic hypertrophy: a systematic review and meta-analysis. ( 24754254 )
2014
18
Estrogen receptor beta agonist LY500307 fails to improve symptoms in men with enlarged prostate secondary to benign prostatic hypertrophy. ( 25348255 )
2014
19
Re: Editorial comment on constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial: S. A. Kaplan J Urol 2013; 190: 1818-1819. ( 24892642 )
2014
20
Preparation, characterization and stability study of dutasteride loaded nanoemulsion for treatment of benign prostatic hypertrophy. ( 25587300 )
2014
21
Successful minimally-invasive management of a case of giant prostatic hypertrophy associated with recurrent nephrogenic adenoma of the prostate. ( 23565707 )
2013
22
Re: Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial. ( 24120797 )
2013
23
A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. ( 23642948 )
2013
24
Alpha-1 adrenergic antagonists in aircrew for the treatment of benign prostatic hypertrophy. ( 23305000 )
2013
25
Correlation of transrectal and transabodominal ultrasound measurement of transition zone volume with post-operative enucleated adenoma volume in benign prostatic hypertrophy. ( 24876907 )
2013
26
American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited. ( 22123290 )
2012
27
Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial. ( 23089217 )
2012
28
Sphaeranthus indicus attenuates testosterone induced prostatic hypertrophy in albino rats. ( 21503998 )
2011
29
The early days of prostatectomy for benign prostatic hypertrophy. ( 22132481 )
2011
30
Carvedilol for the treatment of benign prostatic hypertrophy in patients with heart failure? ( 21962427 )
2011
31
Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. ( 21171937 )
2011
32
Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy. ( 21221201 )
2010
33
Serenoa repens in benign prostatic hypertrophy: analysis of 2 Italian studies. ( 20944533 )
2010
34
Effect of Benincasa hispida fruits on testosterone-induced prostatic hypertrophy in albino rats. ( 24688153 )
2010
35
Acute colonic obstruction due to benign prostatic hypertrophy. ( 19405320 )
2009
36
Impact of alpha 1-adrenergic antagonist use for benign prostatic hypertrophy on outcomes in patients with heart failure. ( 19576359 )
2009
37
[Oxidative stress in prostate hypertrophy and carcinogenesis]. ( 19644150 )
2009
38
Increased frequency and nocturia in a middle aged male may not always be due to Benign Prostatic Hypertrophy (BPH): a case report. ( 19946479 )
2009
39
Management of benign prostatic hypertrophy-related urinary retention: current trends and perspectives. ( 20027550 )
2009
40
Benign prostatic hypertrophy. ( 19737273 )
2009
41
Pharmacological management of benign prostatic hypertrophy with phosphodiesterase-5 inhibitors. ( 20017412 )
2009
42
Transurethral resection of the prostate (TURP)--in the treatment of benign prostatic hypertrophy (BPH) in Mekelle, Ethiopia. ( 19743783 )
2009
43
Increased frequency and nocturia in a middle aged male may not always be due to benign prostatic hypertrophy: a case report. ( 20184712 )
2009
44
Characteristic gene expression profiles of benign prostatic hypertrophy and prostate cancer. ( 19639170 )
2009
45
Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy. ( 18728700 )
2008
46
[5-Alpha reductase inhibitors--benign prostatic hypertrophy and much more]. ( 18570285 )
2008
47
[Influence of dihydrotestosterone deficit on treatment of prostatic diseases regarding to contemporary methods of prostatic hypertrophy treatments]. ( 19205388 )
2008
48
Testosterone levels in benign prostatic hypertrophy and prostate cancer. ( 18362481 )
2008
49
Medical management of benign prostatic hypertrophy. ( 18163946 )
2007
50
Incontinence related to management of benign prostatic hypertrophy. ( 18179990 )
2007

Variations for Prostatic Hypertrophy

Expression for Prostatic Hypertrophy

Search GEO for disease gene expression data for Prostatic Hypertrophy.

Pathways for Prostatic Hypertrophy

GO Terms for Prostatic Hypertrophy

Biological processes related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.71 ADRA1A CD36 FGF8
2 negative regulation of gene expression GO:0010629 9.69 CD36 ESR1 PGR
3 transcription initiation from RNA polymerase II promoter GO:0006367 9.63 AR ESR1 PGR
4 positive regulation of cytosolic calcium ion concentration GO:0007204 9.61 ADRA1A CD36 ESR1
5 positive regulation of phosphorylation GO:0042327 9.52 AR EGF
6 positive regulation of MAPK cascade GO:0043410 9.5 ADRA1A AR CD36
7 positive regulation of mitotic nuclear division GO:0045840 9.49 EGF FGF8
8 sex differentiation GO:0007548 9.48 AR SRY
9 androgen metabolic process GO:0008209 9.4 CYP19A1 ESR1
10 uterus development GO:0060065 9.37 CYP19A1 ESR1
11 steroid hormone mediated signaling pathway GO:0043401 9.33 AR ESR1 PGR
12 prostate gland growth GO:0060736 9.26 AR CYP19A1
13 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 8.96 AR PGR
14 mammary gland alveolus development GO:0060749 8.8 AR EGF ESR1

Molecular functions related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 lipid binding GO:0008289 9.62 AR CD36 ESR1 PGR
2 ATPase binding GO:0051117 9.43 AR ESR1 PGR
3 steroid hormone receptor activity GO:0003707 9.33 AR ESR1 PGR
4 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding GO:0004879 9.13 AR ESR1 PGR
5 steroid binding GO:0005496 8.8 AR ESR1 PGR

Sources for Prostatic Hypertrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....